Excess annual economic burdens from nosocomial infections caused by multi-drug resistant bacteria in Thailand [0.03%]
泰国多重耐药细菌医院感染的年度经济负担过高
Tuangrat Phodha,Arthorn Riewpaiboon,Kumthorn Malathum et al.
Tuangrat Phodha et al.
Background - Antimicrobial resistance (AMR) is a major health threat worldwide as it brings about poorer outcomes and places economic burdens to society. This study aims to estimate the economic burdens from nosocomial infections (NI) cause...
HCV elimination plan leads to significant benefits in managing liver-related diseases and hospital interventions: a regional simulation [0.03%]
丙型肝炎消除计划在管理肝脏相关疾病和医院干预方面带来了显著益处：区域模拟研究
Giovanni Cenderello,Lucia Taramasso,Domenico Marra et al.
Giovanni Cenderello et al.
Objectives: This article presents a 3-year budget impact simulation on the effects of a chronic Hepatitis C (HCV) eradication plan in real-life costs incurred by the Regional Health Service. ...
Looking for Her (2+): A systematic review of the economic evaluations of Trastuzumab in early stage HER 2 positive breast cancer [0.03%]
寻找她（二）——曲妥珠单抗治疗HER2阳性早期乳腺癌的系统经济学评价研究
Panagiotis Petrou
Panagiotis Petrou
Introduction: Breast cancer, the second most common cancer in women, exerts a multidimensional grave effect on affected women. Among the several subtypes of breast cancer, the overexpression of the human epidermal growth ...
Long-term health benefits of stroke prevention with apixaban versus vitamin K antagonist warfarin in patients with non-valvular atrial fibrillation in Germany: a population-based modelling study [0.03%]
在德国采用阿哌沙班和华法林治疗非瓣膜性房颤的卒中预防：基于人口的建模研究长期健康效益比较
Sebastian Himmler,Malina Müller,Dennis Ostwald et al.
Sebastian Himmler et al.
Background: Patients with non-valvular atrial fibrillation (NVAF) have a five times higher stroke risk. For more than 50 years, vitamin K antagonists (VKAs) have been the primary medication for stroke prevention. Apixaban...
The direct and indirect costs of epilepsy in Poland estimates for 2014-2016 years [0.03%]
2014-2016年波兰癫痫的直接和间接经济损失估算
Aneta Mela,Anna Staniszewska,Witold Wrona et al.
Aneta Mela et al.
Background: According to the current data, around 1% of the Poland population have epilepsy, which comprises about 400,000 people. This group of patients requires life-long therapy including both drug therapy and hospital...
A discrete choice experiment to investigate patient preferences for HIV testing programs in Bogotá, Colombia [0.03%]
一项离散选择试验调查了哥伦比亚波哥大市居民对于艾滋病检测项目的偏好
Ben F M Wijnen,Ruben P L B Van Engelen,Jan Ostermann et al.
Ben F M Wijnen et al.
Background: To assess patients' preferences for HIV testing in Colombia. Methods: A discrete choice experiment was used to assess prefe...
Cross-national drug price comparisons with economic weights in external reference pricing in Germany [0.03%]
德国外部参考定价的跨国药品价格比较及经济权重的影响分析
Jörg Mahlich,Jörn Sindern,Moritz Suppliet
Jörg Mahlich
Background: Since 2012, the pharmaceutical reimbursement legislation in Germany has been applying external reference pricing that uses country-specific economic weights for foreign prices. However, the law does not specif...
Psychometric testing of the health-related quality of life measurement, SF-36v2, in the general population of Thailand [0.03%]
泰国SF-36v2健康相关生活质量测量工具的一般人口心理计量学测试
Krittaphas Kangwanrattanakul,Titinun Auamnoy
Krittaphas Kangwanrattanakul
Background: The SF-36v2 is commonly used instrument worldwide. Nevertheless, it lacks the evidence of psychometric testing and health-related quality of life (HRQoL) level among the general Thai population. Therefore, thi...
Comparison of stroke- and bleed-related healthcare resource utilization and costs among patients with newly diagnosed non-valvular atrial fibrillation and newly treated with dabigatran, rivaroxaban, or warfarin [0.03%]
非瓣膜性房颤新诊断且新接受达比加群、利伐沙班或华法林治疗的患者相关住院和出血医疗资源利用及费用的比较研究
Adrienne M Gilligan,Jessica Franchino-Elder,Xue Song et al.
Adrienne M Gilligan et al.
Background: This is one of the first head-to-head real-world evidence studies comparing stroke-related and bleed-related healthcare and resource utilization (HCRU) and costs among non-valvular atrial fibrillation (NVAF) p...
The evolving role of patient advocates in rare cancers: opportunities and challenges [0.03%]
罕见癌症患者的倡导者角色：机遇与挑战
Ornella Gonzato,Alessandro Gronchi
Ornella Gonzato